Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
9.73
-0.49 (-4.75%)
Mar 31, 2025, 1:14 PM EDT - Market open
Company Description
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.
Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018.
Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich LifeSciences, Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Sep 25, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Snehal Patel |
Contact Details
Address: Building 14, 3992 Bluebonnet Drive Stafford, Texas 77477 United States | |
| Phone | 832 819 3232 |
| Website | greenwichlifesciences.com |
Stock Details
| Ticker Symbol | GLSI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.75 |
| CIK Code | 0001799788 |
| CUSIP Number | 396879108 |
| ISIN Number | US3968791083 |
| Employer ID | 20-5473709 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Snehal S. Patel | Chief Executive Officer, Chief Financial Officer and Director |
| Eric Rothe | Founder and Independent Director |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer and Director |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical and Regulatory Affairs |
| Dr. Christine T. Fischette Ph.D. | Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 1, 2024 | ARS | Filing |
| Nov 1, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 17, 2024 | EFFECT | Notice of Effectiveness |
| Oct 11, 2024 | UPLOAD | Filing |
| Oct 7, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 14, 2024 | 10-Q | Quarterly Report |